Table 3. AEs of apatinib plus pemetrexed or docetaxel in advanced NSCLC with brain metastasis.
| AEs | Apatinib plus CT, n (%) | |
|---|---|---|
| Any grade | Grade 3 or 4 | |
| Alopecia | 22 (62.86) | 2 (5.71) |
| Nausea | 23 (65.71) | 2 (5.71) |
| Fatigue | 20 (57.14) | 5 (14.29) |
| Thrombocytopenia | 18 (51.43) | 5 (14.29) |
| Vomiting | 17 (48.57) | 2 (5.71) |
| Neutropenia | 16 (45.71) | 8 (22.86) |
| Hypertension | 16 (45.71) | 3 (8.57) |
| HFS | 15 (42.86) | 5 (14.29) |
| Anemia | 15 (42.86) | 6 (17.14) |
| Proteinuria | 12 (34.29) | 4 (11.43) |
| Abnormal liver function | 12 (34.29) | 3 (8.57) |
| Rash | 10 (28.57) | 5 (14.29) |
| Diarrhea | 8 (22.86) | 2 (5.71) |
| Paronychia | 7 (20.00) | 2 (5.71) |
| Pruritus | 6 (17.14) | 2 (5.71) |
| Fluid retention | 4 (11.43) | 2 (5.71) |
| Hypomagnesemia | 3 (8.57) | 1 (2.86) |
AEs, adverse events; NSCLC, non-small cell lung cancer; CT, chemotherapy; HFS, hand-foot syndrome.